On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Chembio Diagnostics, Inc. (CEMI) Receives Up To $13.2M by U.S. Government for Rapid POC Zika Test and Related Products

Chembio Diagnostics, Inc. (NASDAQ: CEMI) has received a contract for up to $13.2 million in funding by the U.S government (http://nnw.fm/Tfx2x). This includes funding from the U.S. Department of Health and Human Services (HHS), Biomedical Advance Research and Development Authority (BARDA), and the Office of the Assistant Secretary for Preparedness and Response. The new contract is for the development and sale of Chembio’s quick point-of-care (POC) Zika tests and its other Zika products.

“We are very happy to receive this BARDA contract as it will allow the company to further develop the DPP® Zika IgM/IgG Assays, complete key clinical trials, and complete important U.S. regulatory submissions. Given the limitations of laboratory-based Zika tests, we believe Chembio’s POC DPP® Zika IgM/IgG Assays will become essential tools in the battle against the Zika virus, which is likely to endanger millions of people, in both the U.S. and abroad in the coming years, especially pregnant women,” Chembio CEO John Sperzel stated in the news release.

According to Chembio, current tests for Zika have limited utility. This is because the time between the initial exposure to Zika and the time where antibodies are detectable, also known as seroconversion, are only accurate for a short amount of time. After seroconversion, it is recommended to have more antibody tests to identify whether or not it is the Zika virus. A commitment of $5.9 million has been given for Chembio’s DPP® Zika IgM/IgG Assay and DPP® Micro Reader. This will provide results during patient consultations. This system detects IgM and IgG antibodies within 15 minutes using a blood sample of 10uL.

The option for a further $7.3 million has been put forward for the development, clinical trial, and regulatory submissions for the CEMI’s DPP®Zika/Chikungunya/Dengue IgM/IgG Combination Assay. This identifies IgM and IgG antibodies for Zika, Dengue, and Chikungunya at the same time and also gives results within 15 minutes, thanks to a simple fingerstick blood sample of 10uL.

For more information, visit the company’s website at www.chembio.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217